Publication: Why we should be more careful using hydroxychloroquine in influenza season?
Files
Program
KU Authors
Co-Authors
Çelik, Hülya Gamze
Keske, Şiran
Şener, Ülker
Şahin, Şükrü Taylan
Özyıldırım, Aslı
Editor & Affiliation
Compiler & Affiliation
Translator
Other Contributor
Date
Language
Type
Embargo Status
NO
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
The aim of this study was to describe the QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine (HCQ) and its combinations for the treatment of coronavirus disease 2019 (COVID-19). Hospitalized patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received HCQ and had initial and follow-up electrocardiograms performed between March 10 and May 30, 2020 were included. Critical QTc prolongation was detected in 12% of the patients. On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11–30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02–28, p = 0.047) were found to be associated with critical QTc prolongation.
Source
Publisher
Elsevier
Subject
Medicine
Citation
Has Part
Source
International Journal of Infectious Diseases
Book Series Title
Edition
DOI
10.1016/j.ijid.2020.10.080